US Patent
US9388159 — Substituted diazaspiroalkanes as androgen receptor modulators
Composition of Matter · Assigned to University of California San Diego UCSD · Expires 2027-03-27 · 1y remaining
Vulnerability score
30/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects novel compounds that are androgen receptor modulators useful for treating androgen receptor-associated conditions.
USPTO Abstract
This invention provides for compounds of the Formula II: wherein A, B, Het, R 1 , R 2 and R 3 are as described herein. These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.
Drugs covered by this patent
- Erleada (apalutamide) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.